Oct 30, 2024
 in 
Hot Stocks 🔥

Time To Buy Eli Lilly On The Dip? | Nemo

Name of opportunity: 👀

Eli Lilly and Company 

Missed sales estimates: 📉

Eli Lilly is the pharma company behind Mounjaro and Zepbound, popular weight loss drugs. Analysts had predicted revenue of $12.1 billion for Eli Lilly’s third quarter, but the company actually reported $11.4 billion. While that’s 20% up from the year previous, the shortfall has some investors worried. The company has also lowered its full-year non-GAAP EPS guidance to $13.02-13.52, down from $16.10-16.60. As a result, the stock has dropped by 5.74%, putting it into our ‘Biggest Losers Today’ neme. But it’s not all bad news for Eli Lilly…

How hot is this investment opportunity? 🔥🔥🔥

Some analysts, like Geoff Meacham at Citi Research, say that now might be a good time to invest in the stock. It’s been noted that the lower sales are down to wholesalers cutting their inventory, not decreased demand. 

If you check out Eli Lilly on the Nemo app, you will see it is currently considered to be a ‘Buy’. Analysts predict the price might increase from $847.47 to $865.62 in the next 12 months. If you invested $1000, you might profit $16.36.

Analysts say that Eli Lilly’s products mean the drugmaker remains a strong player in the healthcare market. 

This week, Eli Lilly’s drug Mounjaro has been approved for sale in Hong Kong, and the company aims to begin selling it there as early as the end of this year. Mounjaro is a weight loss drug with the active ingredient tirzepeptide, which some studies have shown to be more powerful than semaglutide, the ingredient behind rival Novo Nordisk’s Ozempic and Wegovy drugs. 

A leading pharma stock: 💊

Eli Lilly and Company is engaged in drug manufacturing businesses. It discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. We have covered Eli Lilly before on Hot Stocks, most recently in August when it soared 12.57% in a week.

Which neme?: 🔍

‘Largest US Stocks’, Moderate Volatility Stocks’, ‘Stocks On The Move’, ‘Biggest Losers Today’, ‘Pharma’, ‘Future Tech: World Changing Ideas’, ‘Copy a $10 Trn Asset Manager’, ‘Record Setters So Far In 2024’ and ‘This Week’s Earnings’. 

Download Nemo to check out Eli Lilly. New users can grab our 50% registration bonus. Add up to $50 to your account and we’ll give you a 50% bonus!

Han Tan

Han Tan is Chief Market Analyst at Nemo.money, bringing over a decade of experience in financial markets as both a seasoned journalist and analyst. Known for his sharp insights into stocks, currencies, and commodities, Han has become a familiar face to national audiences through appearances on Bloomberg TV Malaysia, BFM 89.9, and NTV7 — earning him a trusted reputation in financial media. Before joining Nemo, Han served as Market Analyst at Exinity Group from 2019, where his commentary on macroeconomic trends and market-moving news was regularly featured by global outlets including Reuters, Bloomberg, CNN, BBC, and AFP. Today, Han brings that same clarity and depth to Nemo’s community, delivering content-led ideas that empower first-time investors to confidently navigate global markets.